Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Köhne prognostic category and BRAF mutation...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter C.-H. Köhne
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors C.-. Köhne1, F. Rivera2, J. Taieb3, S. Siena4, M. Peeters5, R. Koukakis6, G. Demonty7, J.-. Douillard8
  • 1Klinikum Oldenburg, Oldenburg, Germany, /
  • 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, /
  • 3Paris Descartes University, Sorbonne Paris-Cité Hopital Européen Georges Pompidou, Paris, France, /
  • 4Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milan, Italy, /
  • 5Antwerp University Hospital, Edegem, Belgium, /
  • 6Amgen Ltd, Uxbridge, United Kingdom, /
  • 7Amgen (Europe) GmbH, Zug, Switzerland, /
  • 8Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, St Herblain, France, /


Köhne et al. (Ann Oncol 2002;13:308–17) have previously reported that mCRC can be divided into three prognostic risk groups (high, medium and low risk) on the basis of four baseline clinical parameters: Eastern Cooperative Oncology Group (ECOG) performance status, white blood cell count, alkaline phosphatase, and number of metastatic sites. BRAF mutation is an additional negative prognostic marker in mCRC. In the first-line mCRC study, PRIME, panitumumab + FOLFOX4 significantly improved overall survival (OS) vs. FOLFOX4 alone in the overall RAS WT population. We retrospectively analysed survival outcomes in patients from the PRIME study categorised according to Köhne and BRAF prognostic risk.